Zelira Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain. The Company's lead product, Zenivol, is a cannabinoid-based medicine for treatment of chronic insomnia. The Company is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. It is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care products containing cannabinoids and based on the patented technology of blackseed oil and zinc.